Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients

被引:9
|
作者
Macedo, Luciana Conci [1 ]
Quintero, Fernanda de Cesare [2 ]
Pagliari-E-Silva, Sara [3 ]
Barbosa Pagnano, Katia Borgia [4 ]
Rodrigues, Camila [1 ]
de Alencar, Josiane Bazzo [1 ]
Sell, Ana Maria [2 ]
Laguila Visentainer, Jeane Eliete [2 ]
机构
[1] Univ Estadual Maringa, Biomed & Clin Anal Dept, Post Grad Program Biosci & Physiopathol, BR-87020900 Maringa, Parana, Brazil
[2] Univ Estadual Maringa, Basic Hlth Sci Dept, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
[3] Hosp Canc Maringa, Maringa, Parana, Brazil
[4] Univ Estadual Campinas, Ctr Hematol & Hemoterapia Campinas, Sao Paulo, Brazil
关键词
Myeloproliferative disorders; NECROSIS-FACTOR-ALPHA; PROMOTER POLYMORPHISM; GENETIC POLYMORPHISMS; POLYCYTHEMIA-VERA; SUSCEPTIBILITY; LUNG; REGION;
D O I
10.1016/j.bcmd.2015.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classical chromosome Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of disorders that share clinical, hematological, and histological features. Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) are elevated in patients with MPN. The aim of this study was to verify the association between the polymorphisms of TNF gene (-308G/A and-238 G/A) in BCR-ABL-negative MPN in our population. Blood samples obtained from MPN patients were genotyped for the JAK2V617F mutation and both TNF polymorphisms using PCR-RFLP. Thirty three (26.8%) patients with polycythemia vera (PV), 35 (28.7%) essential thrombocythemia (ET), 22 (17.7%) primary myelofibrosis (PMF), and 33 (26.8%) with unclassifiable MPN (MPNu) were included in the study. The JAK2 V617F mutation was detected in 94 (76.42%) patients. Were observed a significant increase on the frequency of the TNF-238 GA genotype in MPN patients compared to controls (OR = 221, 95% Cl = 1.02-4.80, P < 0.04). The distribution of the genotypes and allelic frequencies of TNF-308 was significantly different among the MPNs, JAK2V617F positive, PV and PMF, and controls. Our data has demonstrated that the polymorphisms on TNF-238 GA, TNF-308 GA were associated to MPN development in this population, triggered by JAK2 V617F mutation. (C) 2015 Published by Elsevier Inc.
引用
收藏
页码:54 / 57
页数:4
相关论文
共 50 条
  • [31] Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
    Shahrabi, Saeid
    Ehsanpour, Ali
    Heidary, Somayyeh
    Shahjahani, Mohammad
    Behzad, Masumeh Maleki
    ONCOLOGY REVIEWS, 2018, 12 (02) : 109 - 120
  • [32] Correlation of JAK2 V617F Mutation Burden with Clinical and Hematologic Characteristics of Myeloproliferative Neoplasms
    Brown, A. F.
    Wang, Y.
    Abu-Ghusson, M. M.
    George, P. A.
    Vadlamudi, K.
    Furmaga, W. B.
    Fan, H.
    LABORATORY INVESTIGATION, 2013, 93 : 321A - 321A
  • [33] JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
    Oh, Stephen T.
    Gotlib, Jason
    EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (03) : 323 - 337
  • [34] V617F mutations of the JAK2 gene in hematological neoplasms
    Mori, N.
    Yoshinaga, K.
    Tada, M.
    Wang, Y-H.
    Shiseki, M.
    Motoji, T.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 81 - 81
  • [35] Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis
    Yoo, E. -H.
    Jang, J. -H.
    Park, K. -J.
    Gwak, G. -Y.
    Kim, H. -J.
    Kim, S. -H.
    Kim, D. -K.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2011, 33 (05) : 471 - 476
  • [36] Detection of the JAK2 V617F Mutation in Urinary Cell-free DNA in Patients with Myeloproliferative Neoplasms
    Hosoi, Hiroki
    Hori, Yoshikazu
    Fukutsuka, Katsuhiro
    Osuga, Mitsuo
    Koh, Yasuhiro
    Mushino, Toshiki
    Hanaoka, Nobuyoshi
    Yamamoto, Nobuyuki
    Ohno, Hitoshi
    Sonoki, Takashi
    INTERNAL MEDICINE, 2024, 63 (14) : 1987 - 1993
  • [37] Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm
    Fleischman, Angela G.
    Aichberger, Karl J.
    Petersen, Curtis L.
    Doratotaj, Shirin
    Bumm, Thomas G.
    Pahl, Heike L.
    Druker, Brian J.
    Deininger, Michael W.
    BLOOD, 2010, 116 (21) : 348 - 348
  • [38] Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
    Pietra, Daniela
    Li, Sai
    Brisci, Angela
    Passarnonti, Francesco
    Rumi, Elisa
    Theocharides, Alexandre
    Ferrari, Maurizio
    Gisslinger, Heinz
    Kralovics, Robert
    Cremonesi, Laura
    Skoda, Radek
    Cazzola, Mario
    BLOOD, 2008, 111 (03) : 1686 - 1689
  • [39] Comparison of JAK2 V617F positive and negative myeloproliferative diseases
    Szilvasi, A.
    Andrikovics, H.
    Meggyesi, N.
    Tamaska, J.
    Halm, G.
    Lueff, S.
    Nahajevszky, S.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Tordai, A.
    Masszi, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 379 - 379
  • [40] Clinical characteristics of JAK2 V617F positive myeloproliferative diseases
    Andrikovics, H.
    Szilvasi, A.
    Meggyesi, N.
    Tamaska, J.
    Halm, G.
    Lueff, S.
    Nahajevszky, S.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Tordai, A.
    Masszi, T.
    BLOOD REVIEWS, 2007, 21 : S124 - S124